Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879023 | 1.00 | NPC1 (0.52) | NPC1CYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL4999787 | 0.91 | NPC1 (0.49) | NPC1CYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL4999791 | 0.91 | NPC1 (0.49) | NPC1CYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL4993650 | 0.88 | THRB (0.56) | NPC1SMN1; SMN2LMNAHPGDHSD17B10 | |
| SCHEMBL4999756 | 0.85 | SMN1; SMN2 (0.52) | CYP1A2CYP2D6CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL4543778 | 0.84 | THRB (0.43) | NPC1SMN1; SMN2LMNAHPGDHSD17B10 | |
| SCHEMBL3959378 | 0.84 | THRB (0.43) | NPC1SMN1; SMN2LMNAHPGDHSD17B10 | |
| SCHEMBL3879826 | 0.84 | GRM4 (0.48) | NPC1SMN1; SMN2GAAHTTRAB9A | |
| SCHEMBL311727 | 0.84 | GRM4 (0.48) | NPC1SMN1; SMN2GAAHTTRAB9A | |
| SCHEMBL4540403 | 0.84 | HDAC1 (0.53) | NPC1CYP1A2SMN1; SMN2HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | claimed |
| US-20090018135-A1 | Methods of treating bowel disorders | AMGEN INC. (US) | 2009-01-15 | — | — | US | claimed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | claimed |
| EP-2139462-B1 | CALCIMIMETIC COMPOUNDS FOR USE IN THE TREATMENT OF BOWEL DISORDERS | AMGEN INC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120232158-A1 | METHODS OF TREATING HYPERACIDIC DISORDERS | YALE UNIVERISTY | 2012-09-13 | — | — | US | disclosed |
| US-8093299-B2 | Methods of treating bowel disorders | AMGEN INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2139462-A2 | CALCIMIMETIC COMPOUNDS FOR USE IN THE TREATMENT OF BOWEL DISORDERS | Amgen Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20090018135-A1 | Methods of treating bowel disorders | AMGEN INC. (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2008121386-A2 | CALCIMIMETIC COMPOUNDS FOR USE IN THE TREATMENT OF BOWEL DISORDERS | AMGEN INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080027052-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASE | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232158-A1 | METHODS OF TREATING HYPERACIDIC DISORDERS | HRH2, GRPR, SLC10A2 | NPC1 361/4885CYP1A2 2124/4885CYP2D6 1344/4885 |
| US-20090018135-A1 | Methods of treating bowel disorders | SLC10A2, FABP2, ALPI | NPC1 2224/4885CYP1A2 1888/4885CYP2D6 2185/4885 |
| US-20080027052-A1 | METHODS FOR TREATING CYSTIC KIDNEY DISEASE | PKD2, PKD1, REN | NPC1 320/4885CYP1A2 4625/4885CYP2D6 4152/4885 |
| US-20080221101-A1 | Calcium receptor modulating agents | CASR, RYR1, RYR2 | NPC1 1243/4885CYP1A2 2608/4885CYP2D6 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.